1-4 of 4
James P. Thomas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors

Howard H. Bailey, Dona B. Alberti, James P. Thomas, Daniel L. Mulkerin, Kimberly A. Binger, Marco M. Gottardis, Robert E. Martell, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3623–3629.
https://doi.org/10.1158/1078-0432.CCR-07-0158
Published: 15 June 2007
View article titled, Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors
Open the PDF for Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Douglas G. McNeel, Jens Eickhoff, Fred T. Lee, David M. King, Dona Alberti, James P. Thomas, Andreas Friedl, Jill Kolesar, Rebecca Marnocha, Jennifer Volkman, Jianliang Zhang, Luz Hammershaimb, James A. Zwiebel, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7851–7860.
https://doi.org/10.1158/1078-0432.CCR-05-0262
Published: 08 November 2005
View article titled, Phase I Trial of a Monoclonal Antibody Specific for α<sub>v</sub>β<sub>3</sub> Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion
Open the PDF for Phase I Trial of a Monoclonal Antibody Specific for α<sub>v</sub>β<sub>3</sub> Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion in another window
Journal Articles

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer

Grace K. Dy, James P. Thomas, George Wilding, Laura Bruzek, Sumithra Mandrekar, Charles Erlichman, Dona Alberti, Kim Binger, Henry C. Pitot, Steven R. Alberts, Lorelei J. Hanson, Rebecca Marnocha, Kendra Tutsch, Scott H. Kaufmann, Alex A. Adjei
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3410–3416.
https://doi.org/10.1158/1078-0432.CCR-04-2068
Published: 02 May 2005
View article titled, A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer
Open the PDF for A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer in another window
Journal Articles

Tissue Examination to Monitor Antiangiogenic Therapy: A Phase I Clinical Trial with Endostatin

Christoph Mundhenke, James P. Thomas, George Wilding, Fred T. Lee, Fred Kelzc, Rick Chappell, Rosemary Neider, Linda A. Sebree, Andreas Friedl
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (11): 3366–3374.
Published: 01 November 2001
View article titled, Tissue Examination to Monitor Antiangiogenic Therapy: <subtitle>A Phase I Clinical Trial with Endostatin</subtitle>
Open the PDF for Tissue Examination to Monitor Antiangiogenic Therapy: <subtitle>A Phase I Clinical Trial with Endostatin</subtitle> in another window